Cincinnati Children's researchers develop first molecular test to diagnose eosinophilic esophagitis

Key points
- Researchers at Cincinnati Children's Hospital Medical Center have developed the first molecular test to diagnose eosinophilic esophagitis (EoE), a chronic upper gastrointestinal disorder.
- Eosinophilic (ee-uh-sin-uh-fil-ik) esophagitis (EoE) is a recently recognized allergic/immune condition.
- Currently the only way to diagnose EoE is with an endoscopy and biopsy of the esophagus.
- Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S.
Researchers at Cincinnati Children's Hospital Medical Center have developed the first molecular test to diagnose eosinophilic esophagitis (EoE), a chronic upper gastrointestinal disorder. The incidence of EoE has skyrocketed since it was first characterized two decades ago.
The test, based on a 96 gene expression profile, "offers an unprecedented opportunity to improve diagnosis and treatment, and a platform approach for other inflammatory diseases," says Marc Rothenberg, MD, PhD, director of allergy and immunology at Cincinnati Children's and senior author of the study. Up to now, gene expression profiling has not yet been well applied to inflammatory diseases, he says.
The study is published in the Dec. issue of the journal Gastroenterology. The lead author of the study is Ting Wen, PhD, a researcher in the Rothenberg lab at Cincinnati Children's.
The researchers used bioinformatics tools to develop the EoE diagnostic panel, which is composed of a 96 gene PCR array - considered the most reliable tool for analyzing the expression of a focused panel of genes.
The panel was developed from a set of esophageal biopsy samples from children diagnosed with EoE and from some children who do not have EoE. The researchers applied the panel to 148 children and adults with EoE and found it identified patients with approximately 96 percent sensitivity and 98 percent specificity. The diagnostic panel was also able to distinguish patients in remission from those who did not have EoE.
The researchers have preliminary evidence that the panel could identify patients likely to have disease relapse following treatment.
In eosinophilic esophagitis, a type of white blood cell (eosinophil) builds up in the tube that connects your mouth to your stomach (esophagus) as a reaction to foods, allergens or acid reflux. When that happens, the eosinophils can inflame or injure the esophageal tissue.
Eosinophilic Esophagitis (EoE)
Eosinophilic (ee-uh-sin-uh-fil-ik) esophagitis (EoE) is a recently recognized allergic/immune condition. A person with EoE will have inflammation or swelling of the esophagus. The esophagus is the tube that sends food from the mouth to the stomach.
In EoE, large numbers of white blood cells called eosinophils are found in the tissue of the esophagus. Normally there are no eosinophils in the esophagus. EoE can occur at any age and most commonly occurs in Caucasian males. The symptoms of EoE vary with age. In infants and toddlers, you may notice that they refuse their food or are not growing properly. School-age children often have recurring abdominal pain, trouble swallowing or vomiting. Teenagers and adults most often have difficulty swallowing. The esophagus can narrow to the point that food gets stuck. This is called food impaction and is a medical emergency.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Digestive Health →
NewsResearchers find hormone that predicts premature death in kidney patients
Researchers at the University of Colorado School of Medicine have found that high levels of a specific hormone can predict which kidney patients will develop heart problems, require dialysis or die prematurely. "This…
10 September 2011
NewsNew Way to Remove Large Polyps, CA First
For the first time in the western United States, a surgical team lead by Elisabeth McLemore, MD, has used a novel operating platform to perform the scarless removal of rectal tumors. Called Trans-Anal Minimally Invasive…
19 August 2011
NewsGenetic variant linked to development of liver cancer in hepatitis C virus carriers
A genome-wide study by researchers at the RIKEN Center for Genomic Medicine, Hiroshima University Hospital and Sapporo-Kosei General Hospital has identified a genetic variant associated with the development of liver…
